Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (4757)	7/6/1998 2:09:00 PM
From: Steve Fancy	Respond to of 6136

Izzy, that's all dependent on where you think the stock will go. Sentiment seems fairly beaten down at the moment...could turn around on further analyst news...could drop further. Ms Wong apparently hasn't issued anything yet, though don't expect much impact ...the big question is what is Doug Lind thinking. I'm extremely confused after this Geneva conference. Don't have any idea who may be potential viable players and who isn't. Other than Remune which wasn't well received, seems their latest deals are much further behind many others. Does seem to be a lot of players right around the corner. Based on recent performance and current stock price, it'll have to move almost 3 1/2 points in two weeks to make much on a July 30, and almost 4 1/2 points by August, after commissions. Course it fell fast. Personally I don't feel great about the stock right now, but as you know this stocks been stickin' it to me for quite a while now...the drop the last few days is like beating a bad bruise. sf